Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer

Growth Factor ◽

Low Dose ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer

The Breast Journal ◽

10.1111/tbj.13516 ◽

2020 ◽

Vol 26 (3) ◽

pp. 368-375

Author(s):

Karen A. Gelmon ◽

Massimo Cristofanilli ◽

Hope S. Rugo ◽

Angela M. DeMichele ◽

Anil A. Joy ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Efficacy and safety of bevacizumab in the treatment of human epidermal growth factor receptor type 2 negative metastatic breast cancer: About a large series in moroccan population

Indian Journal of Cancer ◽

10.4103/0019-509x.146779 ◽

2014 ◽

Vol 51 (3) ◽

pp. 272 ◽

Cited By ~ 1

Author(s):

N Majid ◽

S Boutayeb ◽

H Errihani

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Abstract P1-13-06: Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)

10.1158/1538-7445.sabcs14-p1-13-06 ◽

2015 ◽

Author(s):

James Signorovitch ◽

Jenny Wang ◽

Ruo-Ding Tan ◽

Darren Thomason ◽

Andrew Kageleiry ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Treatment Patterns ◽

Visceral Metastases ◽

Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs17-p1-09-01 ◽

2018 ◽

Cited By ~ 4

Author(s):

HS Rugo ◽

P Kabos ◽

MN Dickler ◽

WJ John ◽

I Smith ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 1B ◽

Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results

10.1158/1538-7445.am2020-ct108 ◽

2020 ◽

Author(s):

Hope S. Rugo ◽

J. Thad Beck ◽

Guy Jerusalem ◽

Hans Wildiers ◽

Peter Kabos ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 1B ◽

Abemaciclib▼ for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer

Cancer Nursing Practice ◽

10.7748/cnp.2020.e1658 ◽

2020 ◽

Author(s):

Pauline Mcllroy

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

Advances in Therapy ◽

10.1007/s12325-020-01552-2 ◽

2020 ◽

Author(s):

Gayathri Nagaraj ◽

Cynthia X. Ma

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Literature Review ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Abstract OT2-04-07: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial)

10.1158/1538-7445.sabcs19-ot2-04-07 ◽

2020 ◽

Author(s):

Jun Masuda ◽

Junji Tsurutani ◽

Norikazu Masuda ◽

Manabu Futamura ◽

Koji Matsumoto ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3

European Journal of Cancer ◽

10.1016/j.ejca.2018.08.011 ◽

2018 ◽

Vol 104 ◽

pp. 21-31 ◽

Cited By ~ 17

Author(s):

Massimo Cristofanilli ◽

Angela DeMichele ◽

Carla Giorgetti ◽

Nicholas C. Turner ◽

Dennis J. Slamon ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

JAMA Network Open ◽

10.1001/jamanetworkopen.2019.16211 ◽

2019 ◽

Vol 2 (11) ◽

pp. e1916211 ◽

Cited By ~ 3

Author(s):

Neil M. Iyengar ◽

Lillian M. Smyth ◽

Diana Lake ◽

Ayca Gucalp ◽

Jasmeet C. Singh ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Human Epidermal Growth Factor ◽